Investigating novel treatments for a brighter tomorrow
See Enrolling StudiesClinical trials are carefully designed research studies that explore if a new medication or device is safe and effective for humans. These studies may also show which medical approaches work best for certain illnesses or groups of people.
Uptown Research Institute is currently enrolling patients in clinical trials for the following:
MindMed-310
This study is designed to evaluate the efficacy of a single dose of 100 µg of MM-120 (D-lysergic acid diethylamide D-tartrate), versus placebo, for the treatment of depression symptoms.
This study is sponsored by Mind Medicine, Inc.
Cybin 003-002
For adults with a diagnosis of Major Depressive Disorder (MDD) currently experiencing a Major Depressive Episode (MDE).
The goal of this study is to evaluate the efficacy, safety, and tolerability of CYB003 15 mg, compared to placebo, in treating symptoms of MDD in adult participants.
This study is sponsored by Cybin.
Learn MoreTranscend TSND201-PTSD-301
For adults living with Post Traumatic Stress Disorder (PTSD)
The purpose of this study is to assess the efficacy, safety, and tolerability of TSND-201 for the treatment of PTSD symptoms compared to placebo
This study is sponsored by Transcend Therapeutics, Inc.
Novartis CGXV813B12201
For adults experiencing an exacerbation of schizophrenia symptoms who require inpatient treatment
The purpose of this study is to assess the safety, tolerability, and efficacy of GXV813 on treating adults living with symptoms of schizophrenia.
This study is sponsored by Novartis.
Maplight ML-007C-MA-211
For adults with schizophrenia who warrant inpatient hospitalization.
The goal of this study is to assess the efficacy, safety, and tolerability of ML-007C-MA compared with placebo in reducing symptoms of schizophrenia in adults experiencing an acute exacerbation of psychosis.
This study is sponsored by Maplight Therapeutics.
Learn MoreNeurocrine-3029
For adults with schizophrenia who warrant inpatient hospitalization.
The goal of this study is to assess the efficacy, safety, and tolerability of NBI-1117568 in adults with schizophrenia.
This study is sponsored by Neurocrine Biosciences, Inc.
Otsuka-00035
Treatment for worsening of symptoms in patients with schizophrenia.
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of SEP-363856 (75 mg to 100 mg /daily) compared to a placebo in adults experiencing an acute exacerbation of schizophrenia.
This study is sponsored by Otsuka Pharmaceutical.
Learn MoreKynexis 5356-CL-002
For adults with schizophrenia who are clinically stable, but require treatment on their cognitive functioning.
The goal of this study is to assess the efficacy, safety, and tolerability of KYN-5356 on treating cognitive impairment in adults living with symptoms of schizophrenia.
This study is sponsored by Kynexis Therapeutics.
Johnson & Johnson 67953964SCH1001
This study is for adults with schizophrenia looking for an adjunctive treatment method.
The purpose of this study is to assess the safety, tolerability, and efficacy of Aticaprant as an adjunctive treatment for adults living with schizophrenia. All participants will continue their current treatment with permitted background antipsychotic medications (oral or long-acting injectable) at the same dose, without change, taken approximately around the same time of the day (if oral) as prior to entering the study.
This study is sponsored by Johnson & Johnson.
Neurocrine-3032
For adults with schizophrenia who do not warrant inpatient hospitalization.
The goal of this study is to assess the efficacy, safety, and tolerability of NBI-1117568 in adults with schizophrenia.
This study is sponsored by Neurocrine Biosciences, Inc.
Maplight ML-007C-MA-212 [De Novo]
This study is indicated for adults with schizophrenia looking for outpatient treatment.
The goal of this study is to assess the long-term efficacy, safety, and tolerability of ML-007C-MA in adult participants living with symptoms of schizophrenia. For this study, ML-007C-MA is taken orally BID (twice a day), approximately 12 hours apart, within approximately 1 hour of consuming food. ML-007C-MA is provided as a tablet in dose strengths of 105/1.5 mg, 105/3 mg, and 165/3 mg. The dose of 210/3 mg requires the ingestion of two 105/1.5 mg tablets. Study drug will be dispensed to participants to take home.
This study is sponsored by Maplight Therapeutics.
Learn MoreBristol Myers Squibb CN012-0068
The purpose of this study is to assess the efficacy, safety, and tolerability of KarXT on voiding dynamics and urological safety in adults living with symptoms of schizophrenia.
Participants will be asked to pass urine into a funnel or special commode connected to a Flowstar Compact Digital Uroflowmeter. This device automatically measures urine flow and volume and provides a standard printout in real time. The device is FDA 510(k) cleared. Post-void Residual Volume Measurement (PVR) test measures the amount of urine left in the bladder after urination. Participants will lie in a supine position, a gel will be applied to the lower abdomen, and PVR will be measured using a portable bladder scanner.
This study is sponsored by Bristol Myers Squibb.
Uptown Research Institute offers an array of clinical trials across a variety of psychiatric and medical conditions.
We follow ethical and legal guidelines to meet FDA requirements, protect patient volunteers, preserve the integrity of the study, and ensure privacy.
In order to participate in a clinical trial, patients must sign an Informed Consent Form. This document describes the rights and responsibilities for participants, including the voluntary nature of participation.
Criteria For Enrollment
Not every person can participate in a clinical trial. All clinical trials have guidelines regarding who can participate, such as:
Inclusion Criteria, or factors that allow someone to participate in a clinical research trial
Exclusion Criteria, or factors that exclude someone from participation in a clinical research trial
Inclusion and exclusion criteria may include factors like:
Age
Type and stage of disease
Previous treatment history
Other medical conditions